Qiagen N.V. (QGEN) Stock Price & How to Invest

QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. It serves more than 500,000 customers across molecular diagnostics, applied testing, academic research, and pharma, with a portfolio of 500-plus proprietary consumables and automated workflows. The December 2025 acquisition of Parse Biosciences pushed its Sample technologies franchise into single-cell analysis, one of five strategic growth pillars the company is steering toward its 2028 goals.

The investment picture is one of a defensive, recurring-revenue diagnostics supplier navigating a mixed demand backdrop. In Q1 2026, reported sales rose about 2 percent to roughly $492 million, but constant-currency sales slipped about 1 percent as weaker QuantiFERON volumes and cautious U.S. Life Sciences demand offset 9 percent constant-currency growth in Sample technologies and strong QIAstat-Dx placements. Management trimmed full-year 2026 guidance to about $2.43 adjusted EPS on roughly $2.1 billion of sales, below prior consensus, framing QGEN as a margin-disciplined operator whose thesis rests on high-growth diagnostics platforms scaling faster than the legacy drags.

QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. A large share of revenue tracks academic, pharma, and life-sciences research budgets, which softened in the U.S. and remain sensitive to funding cycles. Roughly half of sales are outside the U.S., so currency moves materially affect reported results (reported growth outpaced constant-currency growth in Q1 2026). QIAGEN competes against much larger, better-capitalized rivals, and guidance cuts have shown the top line is vulnerable to demand shocks. Integration of acquisitions like Parse Biosciences carries execution risk.

14 analysts publish price targets on QGEN, averaging $44.07 against a $41.40 price as of August 2026, or +6.4%. The published targets run from $36.00 to $49.47, a moderate spread, and the ratings split 8 buy, 7 hold, 0 sell. Over the last six months there has been 1 raise and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full QGEN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Qiagen N.V.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. QIAstat-Dx syndromic testing. QIAstat-Dx, QIAGEN's cartridge-based syndromic panel system, has been a standout with strong constant-currency growth and heavy new-instrument placements. The most optimistic published target, $49.47, assumes this works close to its best case.

The case against. QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. The most pessimistic target, $36.00, is roughly what QGEN is worth if this bites instead.

Read the full bull and bear case on QGEN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Qiagen N.V.'s investor relations page or your broker.

• Revenue (Q1 2026): ~$492M
• Revenue (FY2026 guidance): ~$2.1B
• Adjusted EPS (FY2026 guidance): ~$2.43
• Market cap: ~$8.3B
• Forward P/E: ~16x
• EV/EBITDA: ~13x

Q1 2026 reported sales rose about 2 percent to roughly $492 million while constant-currency sales fell about 1 percent, and management guided full-year sales to about $2.1 billion and adjusted EPS to about $2.43, both below prior consensus. At a roughly $8.3 billion market cap the stock carries a mid-teens forward P/E, valuing it as a steady compounder rather than a high-growth name. The valuation reflects durable consumable revenue and margin discipline against low-single-digit organic growth.

If you want QGEN exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to QGEN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get QGEN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (DFIS), which spreads the position across many companies. Or build it into a focused thematic portfolio, so QGEN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where QGEN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

QGEN is a profitable, diversified diagnostics and sample-prep supplier priced as a mid-teens-multiple compounder rather than a high-growth name.

Whether QGEN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is QGEN a buy or a sell?, and where the stock could go from here in the QGEN stock forecast.

For income investors, whether QGEN pays a dividend and how the payout looks is covered in does QGEN pay a dividend? And to weigh QGEN against a peer, read the full side-by-side comparisons: QGEN vs TMO and QGEN vs DHR.